MedNess

bite-size biopharma and medtech news

January 18, 2024

Subscribe here

Read this newsletter online

MedNess News Highlights this week

FDA Approves KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Read the post

TIVDAK® sBLA Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

Read the post

Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer Provided

Read the post

Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

Read the post

Boehringer Ingelheim and 3T Biosciences signed a second T-cell focused collaboration

Read the post

MedNess Diagnostics

Read more news on
MedNess Diagnostics

MedNess Neuro

Read more news on MedNess Neuro

Onco-This-Week

Drug Approvals

European Commission Approves KRAZATI (adagrasib) for Patients with Advanced NSCLC with a KRASG12C Mutation

“KRAZATI offers an efficacious and tolerable therapeutic option for patients living with advanced KRASG12C -mutated NSCLC and this approval expands the potential treatment options available,” Martin Reck, MD, PhD, Lung Clinic Grosshansdorf, Germany. “With it’s differentiated profile, KRAZATI offers an impactful treatment option for patients living with lung cancer. This…

Read the post

FDA Approves KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

“Today’s approval of KEYTRUDA plus chemoradiotherapy is welcome news and gives patients with newly diagnosed FIGO 2014 Stage III-IVA cervical cancer, for the first time ever, the option of an anti-PD-1-based regimen to treat their cancer,” said Dr. Bradley Monk, oncologist and professor of obstetrics and gynecology at University of…

Read the post

Read more news on
Drug Approvals

Regulatory News

TIVDAK® sBLA Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

“The Phase 3 innovaTV 301 trial demonstrated a favorable benefit/risk profile, including improvement in overall survival, and adds to the overall data supporting TIVDAK as a treatment option for people with recurrent and metastatic cervical cancer who have limited treatment options,” said Roger Dansey, M.D., Chief Development Officer, Oncology at…

Read the post

Update on Zolbetuximab Biologics License Application in U.S.: FDA rejects the application

Moitreyee Chatterjee-Kishore, Ph.D., M.B.A., Senior Vice President and Head of Immuno-Oncology Development, Astellas said, “We remain confident in zolbetuximab’s clinical profile and potential to fill a significant therapeutic gap for those diagnosed with advanced gastric or GEJ cancer whose tumors are CLDN18.2 positive. Astellas is committed to working with the…

Read the post

Read more news on Regulatory News

Trial Results

Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer Provided

“We are encouraged by the responses in these patients who had all progressed on PD1 targeting therapy and made the strategic decision to expand this patient cohort,” said Dr. Andreas Harstrick, CMO and interim Chief Executive Officer of Affimed. “There is a significant unmet need for these patients who have…

Read the post

Read more news on Trial Results

Trial Status

Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

“TTFields therapy has played a critical role in the treatment of newly diagnosed glioblastoma for nearly a decade, and the TRIDENT trial represents the potential evolution of this treatment paradigm by introducing TTFields earlier, at the same time as radiation therapy and temozolomide,” said Asaf Danziger, Novocure’s Chief Executive Officer.…

Read the post

Enrollment opens for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Prof. Casper H.J. van Eijck, MD, PhD, the DURIPANC Study’s Coordinating Investigator and a pancreato-biliary surgeon at Erasmus MC, stated, “While immune checkpoint inhibitors targeting PD1/PDL1 have shown promise in other solid tumors, they have shown limited efficacy thus far in ductal cancer of the pancreas. Findings from our previous…

Read the post

Read more news on Trial Statuses

Business News

Boehringer Ingelheim and 3T Biosciences signed a second T-cell focused collaboration

“At Boehringer Ingelheim, we are committed to transforming patients’ lives. The initial success of our work with 3T gives us confidence that together we can and will expand and accelerate our pipeline of first-in-class T-cell based anti-cancer therapies,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology and Immune Modulation,…

Read the post

AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies

“As we continue to strengthen our oncology portfolio, we believe that in-situ CAR-T cell therapy represents a paradigm shift utilizing genetic medicine concepts,” said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research at AbbVie. “We look forward to working with Umoja’s team to advance next-generation in-situ CAR-T…

Read the post

Read more
Business News

Editor's Desk

Richa Tewari, Managing Director and Contributing Author, Onco-This-Week

Shalini Roy Choudhury, Managing Editor

Anusha Jayaraman, Managing Editor



Siftjit Kaur, Social Media Manager

Himanshi Agarwal, Social Media Manager

Rueben Das, MedNess Neuro



Renjith Mathew, MedNess Diagnostics

Disclaimer

The editors take care to share authentic information. In case of any discrepancies please write

to **newsletter@medness.org**

The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views

and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer to peer mentoring and support.